| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
AIPAC (Active Immunotherapy PAClitaxel): A phase IIb trial in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 (LAG-3Ig fusion protein) or placebo as adjunctive to a standard chemotherapy regimen of paclitaxel
|
Mueller, C.
|
|
|
27 |
S8 |
p. viii14
|
artikel
|
| 2 |
An immunohistochemical PD-L1 diagnostic assay for treatment with durvalumab in urothelial cancer patients
|
Zajac, M.
|
|
|
27 |
S8 |
p. viii8
|
artikel
|
| 3 |
Anti-tumor activity of recombinant human CXCR2-Fc protein
|
Glukhova, K.A.
|
|
|
27 |
S8 |
p. viii10-viii11
|
artikel
|
| 4 |
A phase 1 study of GBR 1302 in subjects with HER2-positive cancers
|
Wermke, M.
|
|
|
27 |
S8 |
p. viii16
|
artikel
|
| 5 |
Assessment of PD-L1 and CD47 expression together with tumor-associated TILs in resectable early stage NSCLC
|
Hall, S.
|
|
|
27 |
S8 |
p. viii3
|
artikel
|
| 6 |
Association between single nucleotide polymorphisms and side effects in nivolumab treated NSCLC patients
|
Bins, S.
|
|
|
27 |
S8 |
p. viii1
|
artikel
|
| 7 |
BMP-4 production by bladder cancer cells favors tumor progression and promotes the development of a pro-tumoral immune environment
|
Dueñas, M.
|
|
|
27 |
S8 |
p. viii10
|
artikel
|
| 8 |
CD47 expression in solid tumors by mRNA in situ hybridization and by immunohistochemistry
|
Kim, W.H.
|
|
|
27 |
S8 |
p. viii7
|
artikel
|
| 9 |
Clinical validation of photochemical internalisation (fimaVacc) – A novel technology for enhancing cellular immune responses to peptide- and protein-based therapeutic cancer vaccines
|
Høgset, A.
|
|
|
27 |
S8 |
p. viii5
|
artikel
|
| 10 |
Clinico-pathological evaluation of alloimunization in breast cancer patients receiving multiple transfusions
|
Sheikh, A.
|
|
|
27 |
S8 |
p. viii14
|
artikel
|
| 11 |
Csk overexpression makes T cell dummy
|
Wälchli, S.
|
|
|
27 |
S8 |
p. viii6-viii7
|
artikel
|
| 12 |
Dendritic cell production from allogenenic donor Cd34+ stem cells and mononuclear cells: Cancer vaccine
|
Unal, A.
|
|
|
27 |
S8 |
p. viii3
|
artikel
|
| 13 |
Drug index
|
|
|
|
27 |
S8 |
p. viii18
|
artikel
|
| 14 |
Dynamics of the global tumor immunome upon treatment with a novel anti-HER2 anthracycline based antibody drug conjugate in breast cancer
|
D'Amico, L.
|
|
|
27 |
S8 |
p. viii13
|
artikel
|
| 15 |
Editorial Board
|
|
|
|
27 |
S8 |
p. ii-iii
|
artikel
|
| 16 |
Effects of supernatant of three-dimensional cultured breast cancer cells on regulatory T cells and programmed cell death-1 positive T cells
|
Kiyomi, A.
|
|
|
27 |
S8 |
p. viii10
|
artikel
|
| 17 |
Enhanced anti-cancer vaccines with a new epitope improvement system
|
Capasso, C.
|
|
|
27 |
S8 |
p. viii2
|
artikel
|
| 18 |
ESMO Society Profile
|
|
|
|
27 |
S8 |
p. v
|
artikel
|
| 19 |
ESMO Symposium on Immuno-Oncology 2016 Officers and Organisation
|
|
|
|
27 |
S8 |
p. vi-vii
|
artikel
|
| 20 |
GBR1302-BEAT® bispecific antibody targeting CD3 and HER2 demonstrates a higher anti-tumor potential than current HER2-targeting therapies
|
Back, J.
|
|
|
27 |
S8 |
p. viii2
|
artikel
|
| 21 |
Generation of immune checkpoint knock-out human antigen-specific T cells via CRISPR/Cas9-mediated genetic engineering
|
Zhang, C.
|
|
|
27 |
S8 |
p. viii1
|
artikel
|
| 22 |
Glial cells as a marker of stem cell-based glioblastoma multiforme treatment effectiveness
|
Zaitsev, S.
|
|
|
27 |
S8 |
p. viii7
|
artikel
|
| 23 |
IL-1b mediates anti-progression activities in renal cell carcinoma by inducing MCP-1
|
Lee, C.-H.
|
|
|
27 |
S8 |
p. viii11
|
artikel
|
| 24 |
Immune cell profiling in CML bone marrow by multiplex IHC
|
Brück, O.
|
|
|
27 |
S8 |
p. viii13
|
artikel
|
| 25 |
Immune cells can cause inappropriate inflammation leading to the miRNAome shift and cell transformation
|
Halytskiy, V.
|
|
|
27 |
S8 |
p. viii7
|
artikel
|
| 26 |
Immune profiling of colorectal cancer in CANScript™ platform deciphers heterogeneity of tumor microenvironment and immune check point phenotype status
|
Biswas, M.
|
|
|
27 |
S8 |
p. viii9
|
artikel
|
| 27 |
Immunological markers of DC-based vaccine antitumor efficacy in patients with NSCLC
|
Inomistova, M.
|
|
|
27 |
S8 |
p. viii11-viii12
|
artikel
|
| 28 |
Immunomodulation and inhibition of tumor growth by a new class of TLR9 agonists – EnanDIM
|
Volz, B.
|
|
|
27 |
S8 |
p. viii6
|
artikel
|
| 29 |
Impact of humoral immune response against p53 on clinical outcome of High-Grade Serous Ovarian Cancer (HGSOC) patients
|
Garziera, M.
|
|
|
27 |
S8 |
p. viii8
|
artikel
|
| 30 |
Improving the efficacy of PDL1 blockade by combination with oncolytic vaccines
|
Capasso, C.
|
|
|
27 |
S8 |
p. viii2
|
artikel
|
| 31 |
Inter-dependency relationships between patient-derived macrophages and circulating tumor cells in co-culture with relevance to novel therapeutic design
|
Khoo, B.L.
|
|
|
27 |
S8 |
p. viii13-viii14
|
artikel
|
| 32 |
Investigating the immunogenic potential of radiation-induced cancer cell death
|
Donaghy, C.
|
|
|
27 |
S8 |
p. viii13
|
artikel
|
| 33 |
KEYNOTE-185: A randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM)
|
Lonial, S.
|
|
|
27 |
S8 |
p. viii16
|
artikel
|
| 34 |
KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma
|
Mateos, M.V.
|
|
|
27 |
S8 |
p. viii15-viii16
|
artikel
|
| 35 |
KEYNOTE-170: Phase 2 study of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS)
|
Michot, J.-M.
|
|
|
27 |
S8 |
p. viii15
|
artikel
|
| 36 |
KEYNOTE-122: Phase 2 study of pembrolizumab versus standard-of-care chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal carcinoma
|
Ng, Q.S.
|
|
|
27 |
S8 |
p. viii15
|
artikel
|
| 37 |
LOH as “the missing instability” potentially underlying the tumor immunogenicity: On the trails of a correlation between fractional allelic loss and response to nivolumab in renal cancer
|
Bersanelli, M.
|
|
|
27 |
S8 |
p. viii12
|
artikel
|
| 38 |
MemoMAB, a novel technology for the banking and screening of cognate human immunoreceptor repertoires
|
Esslinger, C.
|
|
|
27 |
S8 |
p. viii4
|
artikel
|
| 39 |
MYD88 mutations are associated with a high tumor mutational burden
|
Goodman, A.M.
|
|
|
27 |
S8 |
p. viii12
|
artikel
|
| 40 |
Nivolumab immunotherapy in malignant mesothelioma
|
Bhandari, M.
|
|
|
27 |
S8 |
p. viii8-viii9
|
artikel
|
| 41 |
Oncolytic immunotherapy for enabling dendritic cell therapy
|
Parviainen, S.
|
|
|
27 |
S8 |
p. viii2-viii3
|
artikel
|
| 42 |
PD-1 and PD-L1 expression in ovarian cancer
|
Wieser, V.
|
|
|
27 |
S8 |
p. viii3
|
artikel
|
| 43 |
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma: Randomized phase 3 KEYNOTE-204 study
|
Zinzani, P.L.
|
|
|
27 |
S8 |
p. viii17
|
artikel
|
| 44 |
Phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies (NCT02572687); Phase 1a results
|
Lin, C.-C.
|
|
|
27 |
S8 |
p. viii1
|
artikel
|
| 45 |
Preclinical development of tumor-infiltrating lymphocytes (TILs) based adoptive cell transfer immunotherapy (ACT) for patients with advanced ovarian cancer
|
Westergaard, M.C.W.
|
|
|
27 |
S8 |
p. viii4
|
artikel
|
| 46 |
Prognostic value of immune cells within colorectal cancer are determined by analyzing subset densities of tumor associated macrophage and tumor infiltrating lymphocytes
|
Kim, Y.
|
|
|
27 |
S8 |
p. viii5
|
artikel
|
| 47 |
Proteomic signature analysis and application in clinical development of the novel phosphatidylserine-targeting immunotherapy, bavituximab
|
Gerber, D.E.
|
|
|
27 |
S8 |
p. viii9-viii10
|
artikel
|
| 48 |
Role of tumor-derived exosomal arginase-1 in avoiding immune responses by ovarian cancer
|
Czystowska-Kuźmicz, M.
|
|
|
27 |
S8 |
p. viii12-viii13
|
artikel
|
| 49 |
Schedule optimization of a novel tumor-targeted IL-2 variant immunocytokine by integration of human in vivo immune cell kinetics and functional imaging
|
Ribba, B.
|
|
|
27 |
S8 |
p. viii10
|
artikel
|
| 50 |
Table of Contents
|
|
|
|
27 |
S8 |
p. v
|
artikel
|
| 51 |
TACTI-mel (Two ACTive Immunotherapeutics in melanoma): A Phase 1 trial in patients with unresectable or metastatic melanoma receiving IMP321 (LAG-3Ig fusion protein) as an adjunctive therapy to anti-PD-1 therapy with pembrolizumab
|
Mueller, C.
|
|
|
27 |
S8 |
p. viii14
|
artikel
|
| 52 |
Tapping CD4 T cells for cancer immunotherapy
|
Inderberg, E.M.
|
|
|
27 |
S8 |
p. viii4
|
artikel
|
| 53 |
The effector capacity of peripheral blood mononuclear cells (PBMCs) from HER2+ breast cancer (BC) patients treated with chemotherapy and HER2-targeted therapies (ICORG 10-05)
|
Gaynor, N.
|
|
|
27 |
S8 |
p. viii5
|
artikel
|
| 54 |
The novel chromatin modulator cohesin SA1 both modulates and physically interacts with PD-L1 in colorectal cancer: Implications for immunotherapy
|
Roy, P.
|
|
|
27 |
S8 |
p. viii8
|
artikel
|
| 55 |
Title Page
|
|
|
|
27 |
S8 |
p. iv
|
artikel
|
| 56 |
TKI pazopanib impaires immunostimulatory properties of monocytes: Implication for monocyte-derived DC-based anti-cancer vaccine preparation
|
Zdrazilova Dubska, L.
|
|
|
27 |
S8 |
p. viii6
|
artikel
|
| 57 |
Translational research index
|
|
|
|
27 |
S8 |
p. viii19
|
artikel
|
| 58 |
Tumor infiltration by T lymphocytes correlates with the outcome of prostate cancer patients treated with salvage radiotherapy
|
Nardone, V.
|
|
|
27 |
S8 |
p. viii4-viii5
|
artikel
|
| 59 |
Upregulation of self-associated molecular patterns and Siglec receptors on T cells facilitate cancer immune evasion
|
Stanczak, M.A.
|
|
|
27 |
S8 |
p. viii5-viii6
|
artikel
|
| 60 |
UV1 - A peptide-based, therapeutic cancer vaccine targeting the reverse transcriptase subunit of human telomerase (hTERT)
|
Inderberg, E.M.
|
|
|
27 |
S8 |
p. viii11
|
artikel
|
| 61 |
XIST overrides the regulatory effect of miR-194 on its immunomodulatory target PD-L1 in breast cancer
|
Hamed, M.M.
|
|
|
27 |
S8 |
p. viii9
|
artikel
|
Tijdschrift beschrijving